---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-077043"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-09-15T23:59:59+00:00"
generated_at: "2026-06-10T16:14:20.484138+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma gets Nasdaq bid-price deficiency notice; 180-day cure period

## Summary
- Nasdaq notified Citius on Sept 12, 2023 that bid price closed below $1.00 for 30 consecutive business days.
- Company has until March 11, 2024 to regain compliance; must close at $1.00+ for 10 consecutive days.
- If not compliant by March 2024, may be eligible for an additional 180-day period, subject to other listing standards.
- Company is evaluating options; no immediate effect on listing under symbol CTXR.

## SEC filing metadata
- accession: 0001213900-23-077043
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390023077043/0001213900-23-077043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390023077043/ea185196-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-077043
- JSON: https://secwatch.observer/filing/0001213900-23-077043.json
- Plain text: https://secwatch.observer/filing/0001213900-23-077043.txt

## Key facts
- Listing & Compliance Notices
  Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 12, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Pharmaceuticals, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until March 11, 2024, to regain compliance with the Bid Price Rule. If at any time before March 11, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023077043/0001213900-23-077043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.